Genetic drivers of heterogeneity in type 2 diabetes pathophysiology
University of Manchester · Arthritis UK · +216 more institutions
Abstract
Abstract Type 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes 1,2 and molecular mechanisms that are often specific to cell type 3,4 . Here, to characterize the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study data from 2,535,601 individuals (39.7% not of European ancestry), including 428,452 cases of T2D. We identify 1,289 independent association signals at genome-wide significance ( P < 5 × 10 −8 ) that map to 611 loci, of which 145 loci are, to our knowledge, previously unreported. We define eight non-overlapping clusters of T2D signals that are characterized by distinct profiles of…
Citation impact
- FWCI
- 237.97
- Percentile
- 100%
- References
- 70
Authors
369- KSKen Suzuki
University of Manchester, Arthritis UK, The University of Tokyo, The University of Osaka
- KHKonstantinos HatzikotoulasCorresponding
Helmholtz Zentrum München
- LSLorraine Southam
Helmholtz Zentrum München
- HJHenry J. Taylor
National Institutes of Health, University of Cambridge, National Human Genome Research Institute
- XYXianyong Yin
University of Michigan, Statistical Research (United States), Nanjing Medical University
Topics & keywords
- Genome-wide association study
- Type 2 diabetes
- Biology
- Genetic association
- Genetics
- Epigenomics
- Disease
- Genetic architecture
- Good health and well-being
Funding
- UDU.S. Department of Health and Human Services
- ADAmerican Diabetes AssociationAward: 1-19-ICTS-068
- UDU.S. Department of Veterans Affairs
- AHAmerican Heart AssociationAwards: 17POST33650016, 15POST24470131
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- BABrigham and Women's Hospital
- MGMassachusetts General Hospital
- YUYale University
- VUVanderbilt University
- UOUniversity of Pennsylvania
- HUHarvard University
- HHHamilton Health Sciences
- QMQueen Mary University of London
- MUMcMaster University
- RPRegeneron Pharmaceuticals
- NCNational Center for Global Health and Medicine
- VUVanderbilt University Medical Center
- BIBroad Institute
- IPIonis Pharmaceuticals
- MCMedicines Company
- QDQuest Diagnostics
- KCKowa Company
- ZBZora Biosciences
- AAbiomed
- ABARCA Biopharma
- NINational Institute for Health and Care ResearchAwards: 21754, NIHR203308
- BHBritish Heart Foundation
- DODepartment of Health and Social Care
- ICImperial College London
- UOUniversity of Oxford
- ECEuropean CommissionAward: 101017802
- DDaiichi-Sankyo
- NNNovo Nordisk
- TUTechnische Universität München
- NMNanjing Medical University
- TÜTartu Ülikool
- SServier
- VAVersus ArthritisAward: 21754
- GPGuangdong Provincial People's Hospital
- NINational Institutes of HealthAwards: DK126194, 11-22-JDFPM-06, DK105535
- GGenentech
- UOUniversity of North Carolina at Chapel Hill
- PSPerelman School of Medicine, University of Pennsylvania
- MBManchester Biomedical Research CentreAwards: 21754, NIHR203308
- RRespicardia
- MRMedical Research CouncilAwards: MR/W029626/1, MC_PC_14135, MC_UU_00017/1, HDR-23007, MR/W029626/1
- RRIKEN
- HZHelmholtz Zentrum München
- NHNational Heart, Lung, and Blood Institute
- NHNational Human Genome Research Institute
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAward: DK126194
- JRJanssen Research and Development